DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Metropolis Healthcare Limited — Update-Sale or disposal of unit(s)/division(s)/subsidiary-XBRL

NSE 3d ago·27 Aug 2026, 1:56 pm

Metropolis Healthcare

Metropolis Healthcare has informed stock exchanges about an update concerning the disposal of a unit, division, or subsidiary. This notification, filed via XBRL, signals that the company is actively looking to divest a specific business segment. While the exchange filing does not disclose the exact identity of the asset or the financial details of the deal, such corporate actions are generally undertaken to streamline operations, focus on core strengths, or unlock value for shareholders.

For investors, this development is significant as it indicates a strategic shift in the company's portfolio. A sale or disposal can often lead to a one-time gain, potentially boosting short-term profitability, or it may signal a strategic retreat from a non-core area. The move could also free up capital for reinvestment in the company's primary diagnostic business. The market will closely watch for further details to understand the strategic rationale behind this transaction.